SCHEMBL12374491

SCHEMBL12374491

CC(C)(C)OC(=O)[C@@H](N)C1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 15/20 0.44
GAA P10253 1/20 0.41
DPP7 Q9UHL4 7/20 0.40
EPHX1 P07099 3/20 0.40
KCNH2 Q12809 1/20 0.38
DPP8 Q6V1X1 3/20 0.37
DPP9 Q86TI2 2/20 0.37
FAP Q12884 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27696070 1.00 DPP4 (0.44) DPP4GAADPP7EPHX1KCNH2
SCHEMBL15129485 1.00 DPP4 (0.44) DPP4GAADPP7EPHX1KCNH2
Hydrochloric Acid SCHEMBL3222770 0.98 DPP4 (0.42) DPP4GAADPP7EPHX1KCNH2
Hydrochloric Acid SCHEMBL3222764 0.98 DPP4 (0.42) DPP4GAADPP7EPHX1KCNH2
SCHEMBL27570839 0.98 DPP4 (0.41) DPP4GAADPP7EPHX1KCNH2
Ethyne SCHEMBL27874830 0.96 DPP4 (0.41) DPP4GAADPP7EPHX1KCNH2
Hydrochloric Acid SCHEMBL6438617 0.96 DPP4 (0.40) DPP4GAADPP7EPHX1KCNH2
Hydrochloric Acid SCHEMBL27551179 0.96 DPP4 (0.40) DPP4GAADPP7EPHX1KCNH2
Formic Acid SCHEMBL18274671 0.93 DPP4 (0.40) DPP4GAADPP7EPHX1KCNH2
SCHEMBL14978004 0.90 DPP4 (0.36) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371459-A1 DIMERIC PEPTIDE INHIBITORS OF APOPTOSIS PROTEINS Hepagene Therapeutics (HK) Limited (HK) 2021-12-02 US disclosed
EP-2078007-B1 IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2011-08-31 EP disclosed
US-8003695-B2 IKK-beta serine-threonine protein kinase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-08-23 US disclosed
US-8003695-B2 IKK-beta serine-threonine protein kinase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-08-23 US disclosed
US-20100087515-A1 IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS Chroma Terapeutics Ltd (GB) 2010-04-08 US disclosed
US-20100087515-A1 IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS Chroma Terapeutics Ltd (GB) 2010-04-08 US disclosed
WO-2008053182-A1 IKK-β SERINE-THREONINE PROTEIN KINASE INHIBITORS CHROMA THERAPEUTICS LTD. (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371459-A1 DIMERIC PEPTIDE INHIBITORS OF APOPTOSIS PROTEINS BIRC2, BIRC5, BIRC3 DPP4 1412/4885GAA 4075/4885DPP7 427/4885
US-20100087515-A1 IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS IRAK3, IKBKE, IRAK1 DPP4 3419/4885GAA 3885/4885DPP7 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.